title: Oncology pharma costs to exceed $150 billion by 2020.
abstract: Worldwide costs of oncology drugs will rise above $150 billion by 2020, according to a report by the IMS Institute for Healthcare Informatics. Many factors are in play, according to IMS, including the new wave of expensive immunotherapies. Pembrolizumab (Keytruda), priced at $150,000 per year per patient, and nivolumab (Opdivo), priced at $165,000, may be harbingers of the market for cancer immunotherapies.
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics; D000970:Antineoplastic Agents / Q000191:economics*; D016527:Drug Costs / Q000639:trends*; D006801:Humans; D008495:Medical Oncology / Q000191:economics*; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077594:Nivolumab; C582435:pembrolizumab